Market Place
Sourcing Support
ASCO: KRAS upstarts set their sights on NSCLC market
05 Jun 2024 //
PHARMAPHORUM
BMS touts KRAS confirmatory trial win after Amgen`s stumble
30 Mar 2024 //
FIERCE PHARMA
Verastem Granted Fast Track Designation for Avutometinib and Sotorasib
18 Jan 2024 //
BUSINESSWIRE
FDA declines to grant Amgen’s Lumakras full approval in lung cancer
27 Dec 2023 //
ENDPTS
Amgen sticks by Lumakras dose as ESMO data boost confidence
22 Oct 2023 //
FIERCE PHARMA
Verastem Announces Results of RAMP 203 Trial of Avutometinib and LUMAKRAS
14 Oct 2023 //
BUSINESSWIRE
US FDA panel says Amgen lung cancer drug data cannot be relied on
06 Oct 2023 //
REUTERS
Amgen`s late-stage data for lung cancer drug `not adequate` - FDA staff
04 Oct 2023 //
REUTERS
FDA flags `systemic bias` in Amgen`s Lumakras trial
03 Oct 2023 //
FIERCE PHARMA
Amgen Presents Lumakras Plus Chemotherapy Data In First-Line Kras G12C Nsclc
10 Sep 2023 //
PR NEWSWIRE
Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC
28 Aug 2023 //
ONCLIVE
VITRAC Initiates PI Trial with VIC-1911 and G12C Inhibitor Sotorasib
24 Jan 2023 //
BUSINESSWIRE
Sanofi Terminated the Collaboration with Revolution Medicines
08 Dec 2022 //
GLOBENEWSWIRE
Philip Tagari switches Amgen`s discovery lab for insitro`s machine tools
02 Dec 2022 //
ENDPTS
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial
11 Oct 2022 //
GLOBENEWSWIRE
Lumakras With Vectibix Shows Confirmed 30% Objective Response Rate In Patients
12 Sep 2022 //
PRNEWSWIRE
Lumakras Demonstrates Progression-Free Survival Over Docetaxel
11 Sep 2022 //
PRNEWSWIRE
Amgen announces topline data from lumakras® (sotorasib) Phase 3 Trial
31 Aug 2022 //
PRNEWSWIRE
Verastem Oncology Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
WCLC: Amgen`s Lumakras-Keytruda combo data raises a safety flag
07 Aug 2022 //
FIERCEPHARMA
Amgen outlines plan for Lumakras as US rollout hits snag
05 Aug 2022 //
FIERCEPHARMA
Amgen`s blockbuster hopeful Lumakras sees slower than expected sales
12 Jul 2022 //
ENDPTS
Mirati KRAS data are `identical` to Amgen`s, researcher, CEO say
06 Jun 2022 //
FIERCEBIOTECH
Lumakras Codebreak 100 Study Shows 2Year OS Of 32.5% In Patients With NSCLC
10 Apr 2022 //
PRNEWSWIRE
Amgen`s Lumakras posts encouraging results in pancreatic cancer
16 Feb 2022 //
FIERCEPHARMA
Lumakras Shows Encouraging And Clinically Meaningful Anticancer Activity
14 Feb 2022 //
PRNEWSWIRE
Lumakras receives approval for KRAS G12C-mutated advanced NSCLC
20 Jan 2022 //
PRNEWSWIRE
Amgen’s Lumykras receives EU conditional marketing approval
11 Jan 2022 //
PHARMABIZ
City of Hope Researchers Find Improved Treatment Options for Colorectal Cancer
14 Dec 2021 //
BUSINESSWIRE
Amgen reveals new combination data for KRAS inhibitor
12 Oct 2021 //
PHARMATIMES
Amgen`s Lumakras combos disappoint: analysts
09 Oct 2021 //
FIERCEPHARMA
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo
09 Oct 2021 //
FIERCEBIOTECH
Amgen To Present Lumakras Combination Data From Ph1b Study On KRAS G12C
07 Oct 2021 //
RTTNEWS
Mirati moves for an independent future
20 Sep 2021 //
EVALUATE
BI clinical collaboration with Amgen to study BI 1701963 in combo with Lumakras
18 Sep 2021 //
PHARMABIZ
Amgen`s Lumakras combo heads into late-stage colorectal testing
17 Sep 2021 //
FIERCEPHARMA
Amgen to advance KRAS drug combination after improved results in colon cancer
16 Sep 2021 //
BIOPHARMADIVE
LUMAKRAS + Vectibix Shows Better Results In KRAS G12C-Mutated Colorectal Cancer
16 Sep 2021 //
PRNEWSWIRE
Health Canada approves Amgen’s Lumakras to treat NSCLC
16 Sep 2021 //
PHARMABIZ
Health Canada approves LUMAKRAS (sotorasib)
14 Sep 2021 //
BIOSPACE
UK MHRA approves Amgen’s sotorasib for non-small cell lung cancer treatment
13 Sep 2021 //
PHARMACEUTICALS-TECHNOLOGY
Amgen`s Lumakras set for rollout in England thanks to NHS access
10 Sep 2021 //
FIERCEPHARMA
NHS lung cancer patients to receive Amgen’s tumour-stopping drug
09 Sep 2021 //
PHARMAFILE
Amgen reports encouraging results from Phase II trial of Lumakras for NSCLC
09 Sep 2021 //
CLINICALTRIALSARENA
Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21
08 Sep 2021 //
PRNEWSWIRE
FDA Grants Sotorasib Priority Review Designation For The Treatment
17 Feb 2021 //
PRNEWSWIRE
Weeks after dropping big response data, Amgen lines up priority review sotorasib
17 Feb 2021 //
ENDPTS
Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
01 Feb 2021 //
PRESS RELEASE
Amgen`s KRAS drug pads its case for approval
30 Jan 2021 //
FIERCE BIOTECH
Amgen’s sotorasib provides durable responses in NSCLC trial
29 Jan 2021 //
CLINICALTRIALSARENA
Amgen`s Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid
28 Jan 2021 //
PRNEWSWIRE
Amgen files KRAS inhibitor sotorasib with EMA
25 Dec 2020 //
CNBC
Amgen Submits Sotorasib Marketing Authorization Application To The EMA
22 Dec 2020 //
PRNEWSWIRE
Amgen Submits Sotorasib Marketing Authorization Application To The EMA
22 Dec 2020 //
PRNEWSWIRE
Amgen Submits Sotorasib Marketing Authorization Application To The EMA
22 Dec 2020 //
PRNEWSWIRE
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced
16 Dec 2020 //
YAHOO
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced
16 Dec 2020 //
PRNEWSWIRE
Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
08 Dec 2020 //
FIERCE BIOTECH
Applied BioMath, LLC Announces Collaboration with Antengene for Systems
08 Dec 2020 //
PRNEWSWIRE
Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
08 Dec 2020 //
FIERCE BIOTECH
